Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
Bezisterim showed statistically significant improvements in fatigue, malaise, and cognitive symptoms among Long COVID patients with high baseline symptom burden, with a safety profile similar to placebo. Experts and patient advocates described the results as the most promising to date, supporting a…
Bezisterim demonstrated statistically significant improvements in fatigue, post-exertional malaise, and cognitive impairment among Long COVID patients with high baseline symptom burden, with a safety profile similar to placebo. All advisors recommend advancing to Phase 3 trials.Original document: B…
Topline results from a Phase 2 trial show bezisterim improved neurological symptoms in Long COVID patients with high baseline fatigue, cognitive impairment, or post-exertional malaise, with a safety profile similar to placebo. No endpoints reached significance in the overall population, but signifi…